Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more
Radiopharm Theranostics Limited (RDPTF) - Net Assets
Latest net assets as of December 2024: $52.00 Million USD
Based on the latest financial reports, Radiopharm Theranostics Limited (RDPTF) has net assets worth $52.00 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($92.45 Million) and total liabilities ($40.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $52.00 Million |
| % of Total Assets | 56.25% |
| Annual Growth Rate | -12.02% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 42.98 |
Radiopharm Theranostics Limited - Net Assets Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Radiopharm Theranostics Limited (2022–2025)
The table below shows the annual net assets of Radiopharm Theranostics Limited from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $42.87 Million | +56.73% |
| 2024-06-30 | $27.35 Million | -39.99% |
| 2023-06-30 | $45.58 Million | -27.61% |
| 2022-06-30 | $62.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Radiopharm Theranostics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11490878300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $190.52 Million | 425.35% |
| Total Equity | $44.79 Million | 100.00% |
Radiopharm Theranostics Limited Competitors by Market Cap
The table below lists competitors of Radiopharm Theranostics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xchanging Solutions Limited
NSE:XCHANGING
|
$17.87 Million |
|
Asia Pacific Wire & Cable Corp Ltd
NASDAQ:APWC
|
$17.88 Million |
|
Gseven Co Ltd
TWO:2937
|
$17.88 Million |
|
YOC AG
F:YOC
|
$17.88 Million |
|
Petros Petropoulos AEBE
AT:PETRO
|
$17.87 Million |
|
Mr Bricolage
PA:ALMRB
|
$17.87 Million |
|
Sungwoo Electronics Co. Ltd
KQ:081580
|
$17.86 Million |
|
Credo Brands Marketing Limited
NSE:MUFTI
|
$17.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Radiopharm Theranostics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 28,122,562 to 44,792,004, a change of 16,669,442 (59.3%).
- Net loss of 38,342,457 reduced equity.
- New share issuances of 53,977,902 increased equity.
- Other factors increased equity by 1,033,997.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.34 Million | -85.6% |
| Share Issuances | $53.98 Million | +120.51% |
| Other Changes | $1.03 Million | +2.31% |
| Total Change | $- | 59.27% |
Book Value vs Market Value Analysis
This analysis compares Radiopharm Theranostics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.60x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.60x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $0.23 | $0.01 | x |
| 2023-06-30 | $0.12 | $0.01 | x |
| 2024-06-30 | $0.06 | $0.01 | x |
| 2025-06-30 | $0.02 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Radiopharm Theranostics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -85.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1055.27%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.93x
- Recent ROE (-85.60%) is above the historical average (-95.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -48.19% | -343550.89% | 0.00x | 1.32x | $-36.64 Million |
| 2023 | -77.98% | -11838.59% | 0.00x | 1.69x | $-39.05 Million |
| 2024 | -170.50% | -16024.28% | 0.00x | 2.56x | $-50.76 Million |
| 2025 | -85.60% | -1055.27% | 0.04x | 1.93x | $-42.82 Million |
Industry Comparison
This section compares Radiopharm Theranostics Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Radiopharm Theranostics Limited (RDPTF) | $52.00 Million | -48.19% | 0.78x | $17.87 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |